Eckert & Ziegler SE

Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

Eckert & Ziegler receives “Best Managed Companies Award”

Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.

Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.

Eckert & Ziegler SE: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, buy

Eckert & Ziegler SE: Dr. Andreas Eckert, sell

Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 1,105 shares as part of management board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic …

Eckert & Ziegler SE: Dr. Andreas Eckert, Allocation of 1,560 shares as part of management board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic …

Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.

Eckert & Ziegler Completes Change of Legal Form to SE

Eckert & Ziegler Extends Ga-68 Activities in Japan

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177